about
Congenital heart disease and pulmonary arterial hypertension in South America (2013 Grover Conference series)ALDH1A2 (RALDH2) genetic variation in human congenital heart disease.Morphology of the internal elastic lamina in arteries from pulmonary hypertensive patients: a confocal laser microscopy study.Sleep in infants with congenital heart disease.Repair of congenital heart disease with associated pulmonary hypertension in children: what are the minimal investigative procedures? Consensus statement from the Congenital Heart Disease and Pediatric Task Forces, Pulmonary Vascular Research InstitSaudi guidelines on the diagnosis and treatment of pulmonary hypertension: 2014 updatesFunctional classification of pulmonary hypertension in children: Report from the PVRI pediatric taskforce, Panama 2011.A consensus approach to the classification of pediatric pulmonary hypertensive vascular disease: Report from the PVRI Pediatric Taskforce, Panama 2011.Pathophysiological basis for anticoagulant and antithrombotic therapy in pulmonary hypertension.Cardiac catheterization in children with pulmonary hypertensive vascular disease: consensus statement from the Pulmonary Vascular Research Institute, Pediatric and Congenital Heart Disease Task Forces.Decreased plasma ADAMTS-13 activity as a predictor of postoperative bleeding in cyanotic congenital heart disease.Can we start to think about consensus-oriented clinical practices?Factors influencing outcomes in patients with Eisenmenger syndrome: a nine-year follow-up study.Serum Cytokines in Young Pediatric Patients with Congenital Cardiac Shunts and Altered Pulmonary Hemodynamics.Is surgical treatment the cure for patients with congenital heart disease?Saudi Guidelines on the Diagnosis and Treatment of Pulmonary Hypertension: Pulmonary arterial hypertension associated with congenital heart disease.[Two-year follow-up of pulmonary arterial hypertension patients treated with sildenafil].Atrial septal defect in adults: does repair always mean cure?Markers of endothelial dysfunction and severity of hypoxaemia in the Eisenmenger syndrome.Lack of evidence of association between MTHFR C677T polymorphism and congenital heart disease in a TDT study design.Relation of Cytokine Profile to Clinical and Hemodynamic Features in Young Patients With Congenital Heart Disease and Pulmonary Hypertension.Increased tyrosine phosphorylation of platelet proteins including pp125(FAK) suggests endogenous activation and aggregation in pulmonary hypertension.Hypoxia and altered platelet behavior influence von Willebrand factor multimeric composition in secondary pulmonary hypertension.Platelet protease-activated receptor 1 and membrane expression of P-selectin in pulmonary arterial hypertension.Stimulation of human smooth muscle cell proliferation by thrombin involves increased synthesis of platelet-derived growth factor.Lack of tight association between quality of life and exercise capacity in pulmonary arterial hypertension.Measurement, interpretation and use of haemodynamic parameters in pulmonary hypertension associated with congenital cardiac disease.Measurement, interpretation and use of hemodynamic parameters.Morphologic and immunohistochemical features of pulmonary vasculopathy in end-stage left ventricular systolic failure.Plasma von Willebrand factor as a predictor of survival in pulmonary arterial hypertension associated with congenital heart disease.Decreased circulating thrombomodulin is improved by tadalafil therapy in hypoxemic patients with advanced pulmonary arterial hypertension.Capillary hemangiomatosis like-lesions in lung biopsies from children with congenital heart defects.Age-dependent likelihood of in situ thrombosis in secondary pulmonary hypertension.Myocarditis in children and detection of viruses in myocardial tissue: implications for immunosuppressive therapy.NKX2.5 mutations in patients with non-syndromic congenital heart disease.Phosphodiesterase type 5 inhibitors improve microvascular dysfunction markers in pulmonary arterial hypertension associated with congenital heart diseaseRelation of Macrophage Migration Inhibitory Factor to Pulmonary Hemodynamics and Vascular Structure and Carbamyl-Phosphate Synthetase I Genetic Variations in Pediatric Patients with Congenital Cardiac ShuntsAggregation of platelets in whole blood from children with pulmonary hypertensionAbnormal multimeric and oligomeric composition is associated with enhanced endothelial expression of von Willebrand factor in pulmonary hypertensionCirculating platelet aggregates indicative of in vivo platelet activation in pulmonary hypertension
P50
Q26824207-84F038FB-F5D6-4F93-8B15-01C1528BFF49Q30877299-9A36D96C-64B0-4F4C-B5A0-B9C3CC873CA8Q30930827-D3B8082B-C2C8-44DF-B39D-F65A878D054BQ33555091-4EB90C5B-0E1B-4620-BA1A-E35D3E100CB3Q33806004-0CC3D135-D909-4443-9827-9D5DBA9F3D12Q33965904-8C418DC8-3E79-4872-A03C-FC3D0F697E73Q35180290-930E00C5-6F8C-4A4D-A0E5-F00D9F0A3218Q35181115-3BB13CDF-D226-43EC-9237-2FA35BA4198FQ36418069-1D25701C-DFED-47FF-88CE-1914F1EE2AE6Q36734230-F542CD01-44C2-4349-BA93-85900085766AQ36791611-FB5901F3-C6F6-46BD-B18A-D15B893D83BCQ37472246-DC956B76-1D70-4F5A-AD25-A17953A0EFFCQ38681035-8A9FA78F-D693-4B9F-AD06-C9A156A99124Q41079973-4EB13516-536E-4FAF-BED0-ECC614E5EB55Q41546962-A0364A20-F66A-408D-9D17-072D284DFFACQ42728368-A8553B09-72E7-42FB-A49E-6CB45EDEA257Q43080968-FDEFC9B3-F267-4ADE-B247-E24A9C8E7485Q43101531-3AF29F99-CB9B-4431-9151-B9EB3A68DAEAQ46704989-DB08EDF9-5D7D-46E9-BFFB-50D84A444272Q46737982-EAB84464-C3F3-481D-9E19-C73B97E281E7Q46758141-306A0AC2-99ED-4E89-A569-D03CE8729AB2Q46770287-3E74F2A1-8945-4C2F-B96B-CE100A8C964CQ47608817-A638F006-4245-4A27-92A3-FD459E74623EQ47785819-3A5C52C4-1E97-4857-AB98-11622849DC73Q47802716-7CE94260-796A-4815-A102-68E7E463A709Q48394487-4C1DA449-A3BC-4892-A0F6-3F71E9880D6CQ48410840-EB3D7251-B33B-4617-A590-CED69B1B0949Q48432056-A2D63BDA-0D3F-4E3A-87FE-9EF358004476Q49336481-15B99A31-653F-4BE4-B2FE-3F878AEB09ADQ51391250-C736D4F4-F905-4E09-B4DB-0D87C60D019AQ51465423-98A4BBCF-94F5-4018-8479-99B62D6674C9Q51786039-C686228F-74F4-413E-8D82-F794AB2C824CQ53618359-3CA843B2-5F44-4FEA-9F60-6906B6F32592Q54452696-0B07BDB7-619A-4DBD-83E4-76274E4241D5Q54503645-CB03B0B8-16A3-4EB7-ADA5-C1C6AE8657E2Q57807738-B081620D-4CB8-49EB-88D5-817D685A99CCQ64259474-F948F22C-F2DF-4B58-BDA5-0A3508A97D76Q68904646-79A35B78-1498-49D7-93A1-26DEEF3E0606Q72562218-4CAAAD33-EDC9-4BB5-A162-2A1E36136936Q72893238-99A74BE0-8575-4D93-A11A-39578D4366E4
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Antonio Augusto Lopes
@ast
Antonio Augusto Lopes
@en
Antonio Augusto Lopes
@es
Antonio Augusto Lopes
@nl
Antonio Augusto Lopes
@sl
type
label
Antonio Augusto Lopes
@ast
Antonio Augusto Lopes
@en
Antonio Augusto Lopes
@es
Antonio Augusto Lopes
@nl
Antonio Augusto Lopes
@sl
prefLabel
Antonio Augusto Lopes
@ast
Antonio Augusto Lopes
@en
Antonio Augusto Lopes
@es
Antonio Augusto Lopes
@nl
Antonio Augusto Lopes
@sl
P106
P21
P31
P496
0000-0002-8939-2252
P569
2000-01-01T00:00:00Z